GlassScriptPhysician profile
Peter S Friend
NPI 1609825256
$638.56
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $120 · 2022: $31.88.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $138.23 | 2019-2020 | |
| Pacira Therapeutics, INC. | $52.19 | 2019-2020 | |
| Veloxis Pharmaceuticals, INC. | $50.00 | 2019 | |
| Celgene Corporation | $49.16 | 2019 | |
| Radius Health, INC. | $40.54 | 2020 | |
| Ucb, INC. | $36.86 | 2019 | |
| Medtronic, INC. | $31.88 | 2022 | |
| Mallinckrodt Enterprises LLC | $25.25 | 2019 | |
| Horizon Therapeutics Plc | $23.64 | 2019 | |
| Depuy Synthes Sales INC. | $21.81 | 2019 | |
| Lilly USA, LLC | $21.10 | 2020 | |
| Fresenius USA Marketing, INC. | $19.59 | 2019 | |
| Antares Pharma, INC. | $19.53 | 2019 | |
| Covidien LP | $18.29 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $18.27 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $15.78 | 2019 | |
| Kaleo, INC. | $15.60 | 2019 | |
| Shire North American Group INC | $15.01 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.33 | 2019 | |
| Glaxosmithkline, LLC. | $12.50 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Friend listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.